Pharmalot By Ed Silverman Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Biotech By Allison DeAngelis Apollo acquires minority stake in Sofinnova, extending private equity dealmaking in life sciences
Pharmalot By Ed Silverman Greece plans to go to court to seek compensation from Novartis over a bribery scandal
Pharmalot By Ed Silverman Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Defending pharma tax breaks for ads will be challenging, lobbyist says
Health By Melissa Bailey Harvard has one of the best medical schools. Why does it ignore family medicine?
Science Happens! By Carl Zimmer Watch: Episode 4: Can a worm’s lifespan hold the secrets to human aging?
Health By Jennifer Adaeze Okwerekwu Medical students demand an end to pricey exam testing patient care skills
In the Lab By Andrew Joseph and Sharon Begley God, malaria, and wolverine claws: Colbert talks CRISPR with George Church
Business By Rebecca Robbins Inside the decade-long push to turn a Harvard discovery into a blockbuster medicine
Health By Melissa Bailey How a former ‘street kid’ scooped up NIH grants and shook up medical research